Understanding how a specific enzyme affects DNA repair in breast cancer
Investigating PolQ-mediated alternative NHEJ in breast cancer
['FUNDING_R01'] · SLOAN-KETTERING INST CAN RESEARCH · NIH-10576792
This study is looking at how a protein called polymerase theta helps fix DNA damage in breast cancer cells, and it hopes to find new ways to make treatments like radiation and chemotherapy work better by targeting this protein.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | SLOAN-KETTERING INST CAN RESEARCH (nih funded) |
| Locations | 1 site (NEW YORK, UNITED STATES) |
| Trial ID | NIH-10576792 on ClinicalTrials.gov |
What this research studies
This research investigates the role of polymerase theta (Polθ) in the repair of DNA damage in breast cancer cells. It focuses on how defects in DNA repair pathways can lead to aggressive tumor behavior and explores the potential of targeting Polθ to enhance the effectiveness of cancer treatments like radiation and chemotherapy. By studying the interactions of Polθ with other proteins involved in DNA repair, the research aims to uncover new strategies for treating breast cancer more effectively.
Who could benefit from this research
Good fit: Ideal candidates for this research are breast cancer patients, especially those with mutations in BRCA genes or those whose tumors are resistant to standard therapies.
Not a fit: Patients with non-breast cancers or those whose tumors do not exhibit defects in DNA repair pathways may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for breast cancer patients, particularly those with specific genetic mutations.
How similar studies have performed: Previous research has shown promising results in targeting DNA repair mechanisms in cancer, suggesting that this approach could be effective.
Where this research is happening
NEW YORK, UNITED STATES
- SLOAN-KETTERING INST CAN RESEARCH — NEW YORK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SFEIR, AGNEL — SLOAN-KETTERING INST CAN RESEARCH
- Study coordinator: SFEIR, AGNEL
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Breast Cancer, Cancers, neoplasm/cancer